Biomedicines, Vol. 13, Pages 2618: Chemerin and the Gut: From Inflammation to Cancer

Biomedicines doi: 10.3390/biomedicines13112618

Authors:
Elvedin Pljakic
Emin Delic
Irfan Corovic
Mladen Maksic
Dusan Radojevic
Isidora Stanisavljevic
Violeta Mladenovic
Tomislav Nikolic
Lejla Suljic
Emina Corovic Licina
Samir Vucelj
Sabir Sagdati
Kemal Corovic
Nebojsa Igrutinovic
Nina Urakovic
Haris Plojovic
Selma Habibovic
Ahmo Habibovic
Dusan Popovic
Milos Nikolic
Marina Jovanovic

Chemerin, encoded by the RARRES2 gene, is an adipokine with potent immunometabolic functions mediated through CMKLR1, GPR1, and CCRL2. Its regulation is tissue- and context-dependent, conferring dual protective and pathogenic roles. In the upper GI tract, chemerin facilitates immune tolerance in Barrett’s adenocarcinoma and promotes invasion in esophageal and gastric cancers. In pancreatic disease, it acts as a biomarker of acute and chronic injury, while modulating β-cell function and carcinogenesis. In the liver, chemerin contributes to NAFLD/NASH pathogenesis with both anti-inflammatory and pro-steatotic actions, predicts prognosis in cirrhosis, and demonstrates tumor-suppressive potential in hepatocellular carcinoma. In IBD, chemerin exacerbates colitis via impaired macrophage polarization, yet protects epithelial antimicrobial defense, underscoring its context-specific biology. Collectively, these findings position chemerin as a versatile regulator bridging metabolic dysfunction, inflammation, and gastrointestinal malignancy, and as a potential candidate for biomarker development and therapeutic intervention.

Source link

Elvedin Pljakic www.mdpi.com